Your guide to peptides in 2026
Free shipping on orders over $50!
KPV and the FDA: What the July 2026 Vote Covered
Complete Guide to Peptides Editorial Team
This article is provided for general informational purposes only and is not medical advice. Speak to a qualified healthcare professional before making any decisions about peptide use.
KPV rounded out the trio of near-identical 8-6 votes on day one of the PCAC hearing, alongside BPC-157 and TB-500. It’s also the peptide with arguably the thinnest human evidence base of the three, which makes the committee’s decision to recommend it anyway one of the more striking outcomes from the whole two days.
What KPV actually is
KPV is a short tripeptide, three amino acids, derived from a larger hormone called alpha-melanocyte-stimulating hormone. It’s mostly known and used for its anti-inflammatory properties, and the nomination in front of PCAC proposed it specifically for topical use in wound healing and inflammatory skin conditions.
What the evidence actually showed
This is where KPV’s file looks noticeably thinner than some of the other six peptides. FDA’s briefing document found no published human administration study for KPV at all. Not a small trial, not a handful of case reports, nothing. The supporting research consisted of laboratory work on excised skin and formulation stability studies, useful for understanding how the compound behaves outside a living body, but none of it establishes that KPV actually speeds healing or is safe when used on an actual person.
FDA staff were direct about what that means: the absence of human data is an evidence gap, not evidence of safety. That’s a distinction worth sitting with, because it’s easy to read “no safety concerns reported” as “shown to be safe,” when what it actually means here is that nobody’s formally looked yet.
Beyond the missing human data, FDA’s review also flagged the now-familiar set of concerns that came up across most of the seven compounds: unresolved questions around aggregation, immunogenicity, and how formulation and route of administration might affect safety and effectiveness.
The vote
KPV passed 8-6 with one abstention, the same tight margin as BPC-157 and TB-500. The committee recommended it for the 503A list despite FDA staff proposing non-inclusion and despite the near-total absence of human trial data in KPV’s file specifically.
What this means today
Nothing about KPV’s legal status has changed. It isn’t on the 503A Bulks List, and the PCAC recommendation doesn’t put it there automatically. The FDA still has to decide whether to act on the recommendation, run a formal rulemaking process complete with a public comment period, and issue a final rule, a sequence that realistically takes somewhere between eight months and two years.
KPV is also not a component of any FDA-approved drug, and neither the free base nor the acetate form has approved therapeutic labelling. This vote doesn’t change that either. Compounding eligibility and drug approval remain entirely separate questions, and KPV currently sits outside both.
What it would mean in practice
If the FDA eventually adds KPV to the 503A list, a licensed compounding pharmacy would be able to prepare it for a patient under prescription, for the wound healing and inflammatory use the nomination covered. Given how limited the human evidence is right now, it’s also worth watching whether the FDA’s eventual rulemaking asks for additional data before finalising anything, since the gap the agency flagged here is more significant than what it raised for some of the other peptides in this batch.
Until any of that happens, KPV remains available only through the research peptide market, unregulated, without a prescription pathway, and without any human clinical evidence base to draw on beyond laboratory and formulation studies.
We’ll update this page once the FDA responds formally to the July recommendation.